Autopsy report · NCT03911869

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis

“Study terminated due to lack of enrollment of the target population. There were no safety, efficacy, or regulatory interaction involved in the decision to stop enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 9 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Pfizer

Sponsor type

Industry

Conditions

Brain Metastases

Interventions

encorafenib; binimetinib

Participants

13

Sites

25

Countries

Argentina, Australia, Belgium, Italy, United States

Trials that died the same way

• Treatment Resistance Following Anti-cancer Therapies
  “Study terminated due to lack of enrollment that has been compounded by the global COVID-19 pandemic. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.” (89% match in meaning)
• Surgical Treatment of Chronic Neuropathic Pain
  “The study was terminated due to lower than expected enrollment. The decision to terminate the study was not based on any safety or efficacy concerns.” (89% match in meaning)
• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
  “The study was terminated due to low enrollment.” (86% match in meaning)
• Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
  “The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.” (86% match in meaning)
• HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
  “The clinical study was terminated due to the inability to meet target enrollment.” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.